Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.47 |
| ▸ | TUBB | P07437 | 2/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13816283 | 0.87 | ACHE (0.41) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL11974264 | 0.87 | ACHE (0.46) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL9828544 | 0.85 | ACHE (0.54) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL15713195 | 0.85 | ALDH1A1 (0.45) | ACHEMAPTCYP3A4CA9TUBB4A | |
| SCHEMBL14495329 | 0.85 | TSHR (0.47) | ACHEMAPTCYP3A4CA9TUBB4A | |
| SCHEMBL13788860 | 0.85 | TUBB1 (0.53) | ACHEMAPTCYP3A4TUBB4ATUBB | |
| SCHEMBL19237500 | 0.85 | MAPT (0.40) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL22000553 | 0.83 | TUBB4A (0.48) | MAPTCYP3A4TUBB4ATUBBTUBA3C | |
| SCHEMBL26165845 | 0.82 | PTGS2 (0.47) | ACHEMAPTPTGS2MAPK1L3MBTL1 | |
| SCHEMBL11951323 | 0.81 | ACHE (0.50) | ACHEMAPTCYP3A4CA9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018045-B2 | 17-beta-hydroxywithanolides and use thereof in treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-06-25 | — | — | US | disclosed |
| CN-115010584-B | Method for synthesizing aromatic ketone by iron-catalyzed oxidation of tertiary carbon bond breaking of benzyl position | 南京师范大学 | 2023-12-12 | — | — | CN | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| EP-3515449-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-6893627-B2 | Method for treating type 2 diabetes with an extract of Artemisia | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2005-05-17 | — | — | US | disclosed |
| US-20050069598-A1 | Methods for treating disorders using plant extracts | RIBNICKY DAVID M (US) | 2005-03-31 | — | — | US | disclosed |
| US-20030072822-A1 | Methods for treating disorders using plant extracts | RUTGERS, THE STATE OF UNIVERSITY OF NEW JERSEY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | ACHE 767/4885MAPT 4661/4885CYP3A4 376/4885 |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | ACHE 987/4885MAPT 1677/4885CYP3A4 565/4885 |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | ACHE 4424/4885MAPT 4307/4885CYP3A4 1704/4885 |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ACHE 3157/4885MAPT 3027/4885CYP3A4 4780/4885 |
| US-12018045-B2 | 17-beta-hydroxywithanolides and use thereof in treating cancer | HSD17B7, CYP17A1, HSD17B11 | ACHE 3577/4885MAPT 4819/4885CYP3A4 682/4885 |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | ACHE 4390/4885MAPT 1976/4885CYP3A4 1942/4885 |
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | AAAS, PROC, AADAC | ACHE 998/4885MAPT 4494/4885CYP3A4 122/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | ACHE 3502/4885MAPT 4848/4885CYP3A4 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.